Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of DP303c in HER2-positive Advanced Solid Tumors
NCT05810103Phase 1Unknown
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Apr 2023
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of DP303c in HER2-positive solid tumor, sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoints: Maximum Plasma Concentration, Area Under Curve from 0 to last point and 2 more. Status: unknown.
02
Drugs
DP303c
03
Conditions
HER2-positive solid tumor
Beyond the preview
Go deeper on NCT05810103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05810103.